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Background: Paracetamol (acetaminophen) is recommended in most clinical practice guidelines as the first choice
of treatment for low back pain, however there is limited evidence to support this recommendation. The PACE trial
is the first placebo controlled trial of paracetamol for acute low back pain. This article describes the statistical
analysis plan.
Results: PACE is a randomized double dummy placebo controlled trial that investigates and compares the effect of
paracetamol taken in two regimens for the treatment of low back pain. The protocol has been published. The
analysis plan was completed blind to study group and finalized prior to initiation of analyses. All data collected as
part of the trial were reviewed, without stratification by group, and classified by baseline characteristics, process of
care and trial outcomes. Trial outcomes were classified as primary and secondary outcomes. Appropriate descriptive
statistics and statistical testing of between-group differences, where relevant, have been planned and described.
Conclusions: A standard analysis plan was developed for the results of the PACE study. This plan comprehensively
describes the data captured and pre-determined statistical tests of relevant outcome measures. The plan
demonstrates transparent and verifiable use of the data collected. This a priori plan will be followed to ensure
rigorous standards of data analysis are strictly adhered to.
Trial registration: Australia and New Zealand Clinical Trials Registry ACTRN12609000966291
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The PACE study is the largest clinical trial to date of
paracetamol treatment for patients with low back pain.
Here, we describe the study’s pre-determined statistical
analysis plan, which was finalized prior to analyzing the
data set, and to which the investigators will adhere in
analyzing the data from the trial.
The statistical analysis plan was completed and signed
as approved by the study investigators on 3 June 2013.
Participant recruitment was completed in November 2012,
and final participant follow-up was completed in March* Correspondence: cwilliams@georgeinstitute.org.au
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reproduction in any medium, provided the or2013. Following data integrity checks the database will be
locked (June 2013) and the statistical analysis specified in
the statistical analysis plan will be performed in June 2013.Study overview
Design
The PACE study is a randomized double dummy placebo
controlled trial that investigates and compares the effect
of paracetamol taken in two regimens for the treatment
of low back pain. The study is prospectively registered
(ACTRN12609000966291) and a full protocol has been
published [1]. The study enrolled 1,650 people seeking
care for acute low back pain. All participants received
advice to stay active and reassurance of a favorable prog-
nosis. In addition, participants were randomized to receive
study medication containing either active paracetamol orl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion until the primary endpoint ‘recovery from back pain’
or for a maximum of four weeks after randomization.
Follow-up lasted for three months.
Inclusion criteria
Patients were eligible for inclusion in the study if all of
the following criteria were met:
 Had a primary complaint of pain in the area
between the 12th rib and buttock crease, with or
without leg pain;
 Experienced a new episode of low back pain,
preceded by a period of at least one month without
low back pain;
 Had low back pain of less than six weeks’ duration
(in accordance with the Cochrane Collaboration
Back Review Group definition for ‘acute’ pain);
 Had low back pain severe enough to cause moderate
pain (as measured by adaptations of item 7 of the
Short Form-36 Health Survey;
 Did not have known or suspected serious spinal
pathology (for example, metastatic, inflammatory or
infective diseases of the spine, cauda equina
syndrome, spinal fracture);
 Were not currently taking recommended regular
doses of analgesics, including paracetamol;
 Had not undergone spinal surgery within the
preceding six months;
 Did not report serious co-morbidities preventing
prescription of paracetamol, for example, liver or
renal failure;
 Were not currently taking psychotropic medication
for a health condition considered to prevent reliable
recording of study information;
 Were not pregnant or planning to become pregnant
during the treatment period.
Objectives
The primary aim of the PACE study is to establish if
taking paracetamol results in more rapid recovery from
acute low back pain than placebo.
The specific hypotheses to be tested are that:
1. Participants taking time-contingent paracetamol
(4 g per day in divided doses) will have a more
rapid recovery than those receiving placebo
paracetamol.
2. Participants taking ‘as required’ paracetamol (up to
4 g per day) will have a more rapid recovery than
those receiving placebo paracetamol.
3. Participants taking time-contingent paracetamol will
have a more rapid recovery than those taking ‘as
required’ paracetamol.Secondary aims of the study are to establish if taking
paracetamol in a time-contingent manner or ‘as required’
is more effective in reducing pain and disability and im-
proving function, global rating of change, sleep quality
and quality of life than placebo.
A separate analysis plan will be detailed for a health eco-
nomic analysis and is not included in this manuscript.
Unblinding
The statistical analysis plan was written blinded to treat-
ment allocation. Treatment allocations are stored in a
secured location. Statistician(s) will remain blinded and
work with a dummy coded variable for treatment alloca-
tion until the statistical computer code has been validated.
Definition of outcome variables
Definition of primary outcome
The primary outcome is the number of days until recovery
from low back pain. Self-reported pain scores based on a
pain rating scale (0 to 10, where 0 is ‘no pain’ and 10 is the
‘worst possible pain’) were recorded for up to 12 weeks in
a daily pain diary to calculate days to recovery. Partici-
pants were asked to return the diary after they had recov-
ered or 12 weeks had elapsed.
Recovery is defined in two possible ways. The first is
sustained recovery: the first day with a pain score of 0 or
1 on a 0 to 10 pain rating scale that is maintained for
seven consecutive days. The second is first recovery: the
first day that the participant has a pain score of 0 or 1
on a 0 to 10 pain scale.
For the purpose of the primary analysis, the first defin-
ition will used. This definition was selected based on
consensus among study investigators that seven days
pain-free is more meaningful to patients than just one
day. The second definition will be used in a sensitivity
analysis to confirm the robustness of the primary analysis.
Definition of secondary outcome
The secondary low back pain outcomes to be consid-
ered are:
 Pain in last 24 hours: measured using a numerical
rating (0 to 10), where 0 is ‘no pain’ and 10 is ‘worst
possible pain’, assessed at baseline, week 1, week 2,
week 4 and week 12 [2].
 Disability: measured using the Roland Morris
Disability Questionnaire 0–24 scale at baseline,
week 1, week 2, week 4 and week 12 [2].
 Patient-generated measure of function: measured
using the Patient-Specific Functional Scale (0 to 10 scale)
at baseline, week 1, week 2, week 4 and week 12 [2].
 Global rating of change in back pain symptoms from
onset: measured using the Global perceived change
scale (−5 ‘vastly worse’ to 5 ‘completely recovered’)
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week 12 [2].
 Sleep quality over the previous week: measured
using a modification of item 6 of the Pittsburgh
Sleep Quality Index (very bad, fairly bad, fairly good,
very good) assessed at baseline, week 1, week 2,
week 4 and week 12 [3].
 Quality of life: measured using the Short Form-12
version 2 (SF12v2) at baseline, week 4 and week 12 [4].Definition of process variables
Adherence: Three measures of adherence will be con-
sidered. These are the number of tablets the participant
reports they consumed per day until recovery or the end
of the treatment period (28 days) as recorded in the
daily medication diary; the number of tablets con-
sumed by participants as assessed by counts of returned
(remaining) tablets; and the proportion of tablets the
participant reported they consumed of the recommended
number of tablets.
The number of recommended tablets was 6 tablets per
day in three doses until recovery or the end of the four
week treatment period. Adherence was assessed at the
week 4 follow-up point (28 days) and reported on a 0%
to 100% numerical rating scale adapted from the Brief
Adherence Rating Scale [5].
Participant blinding to treatment: At Week 12, partic-
ipants were asked to answer the question ‘Do you believe
the medication in the red box was real paracetamol, the
white was real paracetamol or that neither were real para-
cetamol’. Their responses could be ‘red package contained
real paracetamol; white package contained real paraceta-
mol; or neither package contained real paracetamol.
Satisfaction with treatment: Participants were asked
to rate their satisfaction with treatment at week 12 on a
0 to 6 likert scale, from 0 ‘not at all satisfied’ to 6 ‘ex-
tremely satisfied’.
Concomitant treatments: Participants were asked to
record separately all medication and health-care services
used for their back pain, other than that provided, for
the study at week 4 and week 12. Information for each
additional treatment was provided as free text often
using variable terminology. These will be aggregated using
a common terminology. Medications will be coded using
the Anatomical Therapeutic Chemical Classification Sys-
tem at the fifth level. Other health services will be coded
according to common provider types, for example special-
ist, hospital or emergency department presentation or
admission, physiotherapy, chiropractic, massage therapy,
other allied health, alternative medicine, and other.
Use of study rescue mediation, which could be provided
by the participant’s general practitioner, were captured at
weeks 1, 2 and 4 and will be presented separately.Safety: The safety and tolerability of each paracetamol
regimen will be considered. Information about serious
adverse events (SAE) or adverse events (AE) were cap-
tured at weeks 1, 2, 4 and 12. SAEs, that is, death, life-
threatening illness, hospitalization, substantial disability
or incapacity, and congenital anomaly or birth defect,
were investigated for possible association with the study
medication at the time of reporting. An SAE committee
determined and reported associations of SAEs with study
medication as none, unlikely, possible, probable or defin-
ite. Unblinding and detailed investigation of the SAE was
to be performed if an association with the study medica-
tion was deemed possible, probable or definite. As par-
ticipants were asked to report all medical events or
symptoms that occurred, irrelevant AEs are likely. For
this reason, all AEs, along with SAEs, will be categorized
using the World Health Organization International
Classification of Diseases coding three digit codes (for
example, A09) [6]. All AEs and SAEs will be described
for each group in appendices.
Analysis principles
Primary analyses will be conducted independently by
two analysts who are blinded to group status. The re-
sults of the independent analyses will be compared and
discrepancies in the results will be resolved. Analyses
will be conducted using Stata and/or SAS. The analyses
will be conducted using intention-to-treat (that is, analysed
as randomized). All statistical tests will be two-tailed. Treat-
ment effect for the primary outcome will be considered
significant if P ≤0.05. For the secondary outcomes, treat-
ment effect will be considered significant if P ≤0.01.
We will not impute values unless specified otherwise
(see ‘Methods for handling missing data’). We will report
the number of observations used in each analysis. Sum-
maries of continuous variables that are normally distrib-
uted will be presented as means and SDs or medians
and inter-quartiles for skewed data, whereas categorical
variables will be presented as frequencies and percent-




The PACE study is a three-arm randomized double blind
double dummy placebo controlled trial. Consecutive
patients or people from the community seeking care
for acute low back pain were screened by primary care
clinicians for eligibility.
Treatment allocation
Eligible patients were randomized to one of three groups:
time-contingent paracetamol dose regimen (plus placebo
‘as required’ paracetamol); ‘as required’ paracetamol (plus
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cebo study arm (placebo time-contingent paracetamol
plus placebo ‘as required’ paracetamol). When the study
clinician determined a patient was eligible to enter the
trial, the patient was supplied with a randomized treat-
ment pack containing the study medicines. A research
assistant then contacted the screened patient to confirm
the patient’s eligibility and, after baseline assessment,
instructed them to break the seal on the randomized
treatment pack. Only at this point was the patient con-
sidered randomized to the trial.
Sample size
Sample size calculations were based upon the median
days to recovery being 14 in the time-contingent para-
cetamol group [7], assuming a median days to recovery
of 17 days in comparison groups. A sample size of 550
individuals per arm (n = 1,650) has 80% power to detect
a significant difference of at least three days in median
time to recovery between each active group and the
placebo group, allowing for up to 10% treatment non-
compliance and a two-sided alpha of 0.05. As no prior
knowledge is available regarding a meaningful effect ofTable 1 Data collection and follow up stages
Time point Data captured
Pre-randomisation
Consultation with clinician Inclusion/exclusion criteria; info
Baseline assesment Inclusion/exclusion criteria con
Episode characteristics: duration
presence of leg pain, days of re
perceived risk of pain persisten
Outcome variables: baseline pain
sleep quality (item 6 Pittsburg S
Roland Morris disability question
Week 1
Day 1 to 7 Daily pain rating scale and dail
Day 7 Adverse events, if participant re
analogue scale, GPC, sleep qua
Week 2
Day 8 to 14 Daily pain rating scale and dail
Day 14 Adverse events, if participant re
analogue scale, GPC, sleep qua
Week 4
Day 15 to 28 Daily pain rating scale and dail
Day 28 Adverse events, pain intensity v
Hours absent from work per w
Brief Adherence rating Scale.
Week 12
Day 29 to 84 Daily pain rating scale until rec
Day 84 Adverse events, pain intensity v
hours absent from work per we
satisfaction with treatment, treaparacetamol on low back pain recovery, this effect size
was based on consensus between investigators during
the design of the study.
Data collection and follow up
The different stages of data collection and follow-up are
summarized in Table 1. Baseline assessment was conducted
within 24 hours of referral from the practitioner and before
commencing study treatment (day 1). Participants com-
pleted a daily pain diary until ‘sustained recovery’ or for
84 days (12 weeks), whichever came first. These data
were used to determine the primary outcome (days to
sustained recovery or days to first recovery). The pri-
mary outcome data and secondary outcome data were
collected at week 1, week 2, week 4 and week 12. If a
participant was not recovered by week four (day 28),
additional collection points for primary data occurred
every two weeks until recovery or week 12.
Interim analysis
In the PACE study, paracetamol was used under its
approved label use, therefore no interim analysis was
conducted.rmed consent; type and date of consultation
firmed; date enrolled in the study; demographic data;
of current symptoms, number of previous episode,
duced activity from back pain, feelings of depression,
ce, compensation status, work status, income and health insurance;
intensity visual analogue scale, global perceived change scale (GPC),
leep Quality Index), Patient Specific Functional Scale (PSFS),
naire (RMDQ), Credibility Expectancy Questionnaire, Short Form 12 (SF12v2)
y medication intake
turned to clinician and if offered rescue medication, pain intensity visual
lity, PSFS, RMDQ
y medication intake if not recovered prior
turned to clinician and if offered rescue medication, pain intensity visual
lity, PSFS, RMDQ
y medication intake if not recovered prior
isual analogue scale, GPC, sleep quality, PSFS, RMDQ, SF12v2,
eek (weeks 1–4), additional treatments used (weeks 1–4),
overy or day 84 if not recovered prior
isual analogue scale, GPC, sleep quality, PSFS, RMDQ, SF12v2,
ek (weeks 5–12), additional treatments used (weeks 5–12),
tment blinding questionnaire.
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Trial profile
Flow of patients through the study will be displayed in a
Consolidated Standards Of Reporting Trials (CONSORT)
diagram. We will report the number of screened patients
who met study inclusion criteria, reasons for exclusion
of non-included patients, the number of participants
randomized per group, and the number who completed
follow-up, as shown in Figure 1.
Data integrity
Basic checks will be conducted on all variables to identify
data entry errors (for example by screening for empty cells
and out-of-range values). Errors will be explored and
corrected.
Data required to assess the primary outcome have been
entered into two different study databases throughout the
study. The following process will be conducted to ensure
integrity of primary data:
1. The source data will be confirmed for every
participant. The order of preference for which
source of data will be used in the primary analysis is:Figa. Pain scores recorded by the participant in
returned pain diariesAssessed for eligibility
Lost to follow-up (give reasons) (n=)
Withdrawn from study (give reasons) 
(n=)
Allocated to active time-contingent 
group (n=)
Consumed >70% of recommended 
course of medicine (n=)
Randomized (n=
Allocated to active 'as req
(n=)
Consumed >70% of rec
course of medicine (n=)
Lost to follow-up (give re
Withdrawn from study (g
(n=)
Analysed (n=)
Excluded from analysis (give reasons) 
(n=)
Analysed (n=)
Excluded from analysis (
(n=)
ure 1 Consort flow diagram.b. Pain scores recorded directly online by the
participant
c. Pain scores reported by the participant via
telephone and transcribed by a research assistant
into a paper copy of the participant’s diary or
directly into online database
d. If all the above are missing, a single recovery date
(or information about non-recovery) captured via
correspondence with a participant. When only a
single recovery date was attained by participants,
research assistants confirmed that the
participants ‘recovery’ had occurred for seven
consecutive days of pain score of 0 or 1 out of ten.
e. If all the above were missing, a single date of
recovery (or information about non-recovery of
participants) was captured during correspondence
with the participant’s treating clinician or
nominated secondary contact person.
2. A random 10% sample of daily pain scores will be
cross-checked between the pain diaries and data
entered into the study database. If the upper bound
of the 95% confidence interval of the error rate is
greater than 10%, cross-checking of all participant’s
diaries with entries made into study database (other
than those that were recorded directly by the
participants themselves to the online database) will (n=)
Excluded  (n=)
Not meeting inclusion criteria (n=)





Allocated to double placebo group (n=)
Consumed >70% of recommended 
course of medicine (n=)
asons) (n=)
ive reasons) 
Lost to follow-up (give reasons) (n=)




Excluded from analysis (give reasons) 
(n=)
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which there is an error over the total number of
days data were recorded for each participant.
3. The primary outcome, number of days until
recovery from low back pain, will be derived using
two methods and compared via a statistical program
using available daily pain data entered into the study
or online database and manually by a research
assistant using pain diary data and other sources
(see ‘Data integrity: point 1) recorded in outcome
assessment booklets. Discrepancies will be
investigated and resolved before the final analysis.
An audit of secondary data will be conducted by
cross-checking data written into participant outcome as-
sessment booklets with data entered into the online
database. A random 10% sample of participant booklets
will be cross-checked. Any errors identified in this
process will be corrected. If more than 10% of the data
are in error, another 10% sample will be drawn for further
checks. As an observation can only be checked once, the
acceptable error rate for this new sample will reduce to
9%. If the error rate is again higher than the acceptable
rate (that is, 9%), another 10% sample will be drawn for
checking and the next acceptable error rate will reduce by
1% (that is, 8%). This process will continue until the
observed error rate is below the acceptable threshold.
Methods for handling missing data
The number of missing observations will be reported.
Completeness of primary survival data will be calculated
using the completeness index [8]. Should this exceed
10%, patterns of missing data will be investigated. Partic-
ipants with no available outcome data will be censored
at day one. Participants who are lost to follow-up will be
censored on the day they last provided data. All other
available primary data will be used until recovery or cen-
soring. If any daily pain score is missing before the out-
come ‘recovery for seven consecutive days’ has been
established, we will assume that a 0 or 1 score for pain
did not occur on the missing day/s, that is to say, no re-
covery. This is consistent with our line of questioning
during data collection, where every effort was made to
confirm that recovery (0 or 1 score for pain) had not oc-
curred during periods of missing data or un-established
recovery.
Evaluation of demographics and baseline characteristics
The description of baseline characteristics listed below
will be presented by treatment group. Categorical vari-
ables will be summarized by frequencies or denominators
and percentages. Percentages will be calculated using the
number of patients for whom data is available as the
denominator. Denominators will be systematically reported(for example, nn/NN,%). Continuous variables will be
summarized using standard measures of central tendency
and dispersion, either mean and SD or median and inter-
quartile range.
Demographics and baseline characteristics:
 Age at randomisation
 Gender
 Days since onset of pain
 Previous history of back pain (number of previous
episodes)
 Presence of pain extending beyond the knee
 Number of days that the episode of pain caused
reduced activity
 Depression sub-scale of The Örebro Musculoskeletal
Pain Questionnaire
 Perceived risk of persisting pain from this episode
 Compensation status
 Other medications used
 Socioeconomic indicators (work, income, health
insurance)
 Pain intensity (numerical rating scale)
 Global rating of change in back complaint since
onset of back complaint
 Sleep quality (Item 6 of the Pittsburgh Sleep Quality
Index)
 Disability (Roland Morris Disability Questionnaire)
 Function (Patient Specific Functional Scale)
 Credibility/Expectancy of treatment (Credibility
Expectancy Questionnaire)
 Quality of Life (SF12v2)
Process measures and concomitant treatments
Categorical and continuous measures listed below will
be summarized. When indicated, data will be summa-
rized per group. Again continuous variables will be sum-
marized by use of standard measures of central tendency
and dispersion, either mean and SD or median and
interquartile range. Categorical variables will be summa-
rized by frequencies or denominators and percentages.
Process variables and concomitant treatments:
 Estimated number of patients invited to participate
 Estimated number of patients eligible to participate
 Numbers and proportion of all eligible patients who
chose to participate
 Numbers and proportion of all eligible patients who
did not participate and (where available) reasons for
not participating
 Number and proportion of participants who
completed study follow-up, were lost to follow-up,
withdrew from the study and reason for withdrawal
 Completeness of outcome survival data
 Adherence measures:
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they consumed per day until recovery or the end
of the treatment period (28 days) as recorded in
the daily medication diary;
○ The number of tablets consumed by participants
as assessed by counts of returned (remaining)
tablets;
○ The proportion of tablets the participant
reported they consumed of the recommended
number of tablets report at the end of week 4
 The proportion of participants having concomitant
treatments per group
 Type and frequency of concomitant treatments
 The proportion of participants provided rescue
medication.
Primary analyses
A cox proportional hazards model will be used to assess
the effect of treatment on outcome. The primary out-
come is time from randomization to recovery. Censor-
ship will occur on the day of the last follow-up, or when
the patient was identified as recovered, whichever oc-
curs earlier. Treatment will be a dummy coded variable
representing treatment exposure (0 = placebo, 1 = as
required and 2 = time-contingent). Adjustment will be
made for baseline pain scores as this has consistently
been identified as an important covariate [9].
Three primary comparisons will be conducted. To
account for multiplicity we will employ the following
closed test procedure recommended by Proschan and
Waclawiw [10] to maintain an overall type 1 error rate
of 0.05. First, a global Wald test will be used to assess
the overall null hypothesis that all treatments are
equally effective. If the global Wald test suggests that
the effect of the treatment on at least one group is signifi-
cantly different from the others, indicated by a P <0.05,
the following pairwise comparisons will be conducted:
time-contingent paracetamol will be compared to placebo;
as required paracetamol will be compared to placebo; and
time-contingent paracetamol will be compared to ‘as
required’ paracetamol.
For these pairwise comparisons, again using the Wald
test statistic, a P-value of 0.05 would indicate a signifi-
cant treatment effect. Hazard ratios will be presented
with their 95% confidence intervals along with median
survival times (recovery) for each group with 95% confi-
dence intervals.
The proportional hazards assumption will be tested
with two checks. Firstly by observing survival curves;
crossing of survival curves would indicate violation. Sec-
ondly, a time-dependent covariate will be introduced into
the cox regression model. Beta values and significant in-
teractions with In(time) will be inspected. If there is
clear evidence of violation of the proportional hazardsassumption, we will consider the effect of treatment on
outcome using an unadjusted log rank test.
Secondary analyses
To test the effects of intervention on the secondary con-
tinuous outcomes (see ‘Definition of secondary outcomes’),
between-group comparisons will be conducted using
longitudinal mixed models combining all available post-
randomization measurements. A log-binomial regression
will be used for categorical outcomes (sleep quality) with
robust Poisson regression as backup in case of convergence
issues [11]. The main test will compare the weighted aver-
age combining estimates from the four follow-ups between
the treatment arms. If this is statistically significant we will
proceed to test pairwise differences between groups for
each follow-up separately.
The independent variables will include a dummy-coded
variable indicating group membership, the time at which
the measurement was taken (week 1, week 2, week 4 or
week 12 post randomization), and the four time-by-group
interactions. Adjustment will be made for baseline out-
comes scores. The effect of paracetamol at each of the
four follow-up time points is estimated with the relevant
interaction term. The model will incorporate random




We will explore the influence of different recovery defi-
nitions on the primary outcome of the study. A second
definition, the first day a participant reports a 0 or 1 out
of 10 on a 0 to 10 numerical rating scale, was previously
reported by Hancock et al. [7] to result in a similar event
rate of recovery.
Adjusting for prognostic variables
In addition to baseline pain, the effect of baseline char-
acteristics, which have been suggested to influence re-
covery [9,12], will be assessed. For primary outcomes,
the Cox regression model previously described will be
extended to include the number of previous episodes
of back pain and the duration of the current episode.
Hazard ratios and 95% confidence intervals will be cal-
culated for treatment effect and each covariate. The
proportional hazards assumption will be tested as pre-
viously described. Stratification will be considered in
the event of violation of the proportional hazards as-
sumption. The covariates ‘the number of previous epi-
sodes of back pain’ and ‘the duration of the current
episode’ will be added to the models outlined for sec-
ondary analyses i to assess their influence on second-
ary outcomes.
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The influence of different imputation methods for miss-
ing data will be assessed. Imputation of best case scenar-
ios (for example, missing data point equals a recovered
value (0 or 1)) will be compared to the proposed method
(worst case; missing value equals a non-recovered value
(>1)) in ‘Methods for handling missing data’. These ana-
lyses will be conducted on observations where daily
scores are available, but some days are missing. They will
not be conducted where only a single date of recovery
has been recorded and daily pain scores are available
(see ‘Data integrity’).
Evaluation of serious adverse events and adverse events
The Fisher exact test will be used to compare the incidence
of any AEs (as coded by the World Health Organization
International Classification of Diseases) between groups.
This test will be used as the event rate of AEs is expected
to be low.
SAEs, when reported, were systematically investigated
for potential association with the study treatment. No for-
mal analysis will be conducted to compare SAEs between
groups as the event rate is extremely low. All SAEs will be
reported per group.
Table and figure shells
Additional file 1: Table S1 will report all collected base-
line characteristics of participants by treatment group.
Figure 1 will display the consort flow diagram. Figure two
(not provided) will display Kaplan-Meier survival curves
for each treatment group for recovery to 84 days (12
weeks), with separate panels for each definition of re-
covery. This figure will also detail median recovery time
per group with 95% confidence intervals and P-values
for primary comparisons between groups. Additional
file 1: Table S2 will report secondary outcome variables
by treatment group and effects of treatment. Additional
file 1: Table S3 will report process measures and con-
comitant treatments by treatment group and were ap-
propriate results of statistical comparisons between
groups. All adverse events will be described by treat-
ment group in the manuscript appendices. Results from
sensitivity analyses will be reported in the manuscript.
New information revealed by sensitivity analyses will
displayed graphically or in tabulation in the manuscript.
Otherwise results of the sensitivity analyses will be tabu-
lated in appendices.Additional file
Additional file 1: Table S1. Baseline characteristics. Table S2:
Secondary low back pain outcomes. Table S3: Effects of treatment,
secondary outcomes. Table S4: Process measures.Abbreviations
AE: Adverse events; SAE: Serious adverse events; SD: Standard deviation;
SF12v: Short Form 12 version 2.
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